idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instanz:
Teilen: 
08.11.2018 10:17

Inselspital offers a new form of therapy for leukemia and lymphoma

Monika Kugemann Bereich Kommunikation und Marketing
Universitätsspital Bern

    On 22 October 2018, an innovative new immunotherapy was approved in Switzerland for the treatment of relapses of acute leukemias and lymphomas. Since this week, the Inselspital is the first hospital in Switzerland to be able to offer this new treatment.

    A milestone in cancer therapy: For the first time, patients in Switzerland who suffer from relapsed acute lymphoblastic leukemia or malignant lymphomas can received a personalized form of immunotherapy. Since approval on 22 October 2018, the Inselspital is the first center in Switzerland to be able to offer this new therapy. The treatment is restricted to to young adults with relapsed acute lymphoblastic leukemias and adults with relapsed and refractory aggressive lymphomas.

    Fighting cancer with your own immune system

    "Previous immunotherapies stimulate the body's own defenses which is not particularly targeted," explains PD Dr. med. Urban Novak from the Inselspital. "The new therapy enables the patient’s immune cells to recognize and destroy tumor cells This takes us a step closer to a precise and truly personalized treatment."

    The malignant cells of these patients are resistant to most of the treatments currently used against cancer. This explains the high expectations on this new treatment strategy. The CAR-T therapy utilizes the body's own modified immune cells (so-called CAR-T cells). These cells are taken from the patient, genetically engineered outside the body to enable them to attack the cancer cells and retransfused.

    A center with considerable experience

    By applying the first approved "living drug", the Inselspital is entering groundbreaking territory. Only a few clinics around the world have used it in studies. The manufacturer has chosen to gradually introduce the treatment in Switzerland in a limited number of cancer centers that are very experienced in treating leukemias and lymphoma. At the Inselspital in Bern, the Department of Medical Oncology and the Department of Hematology and Central Hematological Laboratory will jointly be conducting the CAR-T collection, transfusion and treatment.

    Because the drug is currently administered in an inpatient setting, the multidisciplinarly teams can respond quickly if there are signs of side effects. These may include an overreaction of the immune system, temporary neurological failures or infections. Cancer therapies are often extremely strenuous for the patient, and as a rule they are only used in cases where the benefits clearly outweigh the potential risks.

    Research for more targeted cancer therapies

    The Inselspital is highly committed to the research of immunotherapy against cancer. In work that has been underway since 2003 under Head Physician and Director of the Department of Medical Oncology, Prof. Dr. Med. Adrian Ochsenbein, the oncological team has been researching potential new approaches in the treatment of leukemia in a laboratory specialized for tumor immunology. Currently the Inselspital is also the only Swiss center participating in an international study examining the potential of another CAR-T cell construct for treatment of relapsed aggressive lymphomas.

    Immunotherapy for leukemia, lymphoma and solid tumors, the personalized and targeted treatment of cancer are all important research priorities at the University Cancer Center (Tumorzentrum Bern). The Inselspital is the largest center for autologous stem-cell transplantation in Switzerland. This area of focus is being consistently advanced with the new CAR-T therapy.

    //
    Competence Center for Cancer Therapy at Inselspital Bern

    Tumorzentrum Bern – also known as the University Cancer Center Inselspital (UCI) – offers comprehensive advice, treatment and care to cancer patients and their relatives. Thanks to the cooperation of highly qualified experts from all disciplines, optimal care is ensured at all stages of cancer therapy.
    The interdisciplinary Tumor Boards form a central element of treatment. All the involved experts jointly discuss treatment options and determine the best possible therapy in consultation with the patients. Support includes therapy for pain and physiotherapy, palliative care or psychological and pastoral care as part of the comprehensive offer for patients. Tumorzentrum Bern also focuses on further developing existing treatment options for various tumor-based conditions. As such it is involved in research at both the national and international levels.
    //


    Wissenschaftliche Ansprechpartner:

    PD. Dr. med. Urban Novak, Chief Physician, Department of Medical Oncology, Tumorzentrum Bern, Inselspital, University Hospital Bern, Urban.Novak@insel.ch.


    Weitere Informationen:

    http://Inquiries regarding the assignment of patients: onkologie@insel.ch
    http://(recurrent leukemia 18-25 years, recurrent lymphoma in adults)


    Bilder

    Symbolic photo: Department of Hematology and Central Hematological Laboratory
    Symbolic photo: Department of Hematology and Central Hematological Laboratory
    Inselspital, Bern University Hospital
    None

    Microscopic view of a T cell (Tumor immunology and cancer stem cells lab)
    Microscopic view of a T cell (Tumor immunology and cancer stem cells lab)
    Department for BioMedical Research, University of Bern
    None


    Anhang
    attachment icon Inselspital offers a new form of therapy for leukemia and lymphoma

    Merkmale dieser Pressemitteilung:
    Journalisten, Wissenschaftler
    Biologie, Medizin
    überregional
    Forschungs- / Wissenstransfer, Kooperationen
    Englisch


     

    Symbolic photo: Department of Hematology and Central Hematological Laboratory


    Zum Download

    x

    Microscopic view of a T cell (Tumor immunology and cancer stem cells lab)


    Zum Download

    x

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).